文献速递乳房整形与再造

新辅助化疗后即刻乳房重建的结局:时机、并发症与放疗延迟

Outcomes in Patients Receiving Neoadjuvant Chemotherapy Undergoing Immediate Breast Reconstruction: Effect of Timing, Postoperative Complications, and Delay to Radiation Therapy.
PubMed 文献 · Plast Reconstr Surg · 2019-01-01

该回顾性研究纳入128例接受新辅助化疗后行乳房切除术并用组织扩张器即刻乳房重建的患者,发现发生术后并发症者开始放疗时间显著延迟(p=0.021),且体重指数较高(p=0.018),逻辑回归显示BMI与术后并发症相关(OR 1.09,95%CI 1.018-1.167,p=0.013)。

要点

  • 术后并发症显著延迟新辅助化疗后即刻乳房重建患者的放疗开始时间。
  • BMI较高与术后并发症风险增加相关(OR 1.09,95%CI 1.018-1.167)。
  • 新辅助化疗结束至手术的间隔在有无并发症患者间无差异(p=0.692)。

核心结论

  • 新辅助化疗后乳房切除加即刻组织扩张器重建的患者中,术后并发症会延迟放疗开始。
  • BMI较高者更易发生术后并发症,应考虑于接受新辅助化疗且需辅助放疗的肥胖患者使用组织扩张器时。

研究设计与样本

  • 回顾性综述,纳入接受新辅助化疗、乳房切除术及组织扩张器即刻乳房重建的患者共128例。
  • 采用多因素二项逻辑回归分析术后并发症的危险因素,并用独立样本t检验比较有无并发症患者的新辅助化疗时机和放疗开始时间。

主要发现

  • 有并发症患者与无并发症患者相比,放疗开始时间差异有统计学意义(p=0.021),BMI较高(p=0.018)。
  • 新辅助化疗的时机间隔在两组间无差异(p=0.692)。
  • 逻辑回归显示BMI与术后并发症相关(OR 1.09;95%CI 1.018-1.167;p=0.013)。

临床怎么用

  • 对接受新辅助化疗后即刻组织扩张器乳房重建的患者,应关注术后并发症对放疗启动的延迟影响。
  • 对BMI较高的患者,在决定使用组织扩张器时应权衡术后并发症风险及后续辅助放疗需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant chemotherapy is offered to many patients with breast cancer. In patients undergoing mastectomy and immediate breast reconstruction, there is concern that this treatment could increase postoperative complications. The authors characterize which patients are at a higher risk of experiencing a postoperative complication, and assess the impact of postoperative complications on timing of radiation treatment. METHODS: A retrospective review was performed on patients who underwent neoadjuvant chemotherapy with mastectomy and immediate breast reconstruction using tissue expanders. Multivariable binomial logistic regression analysis was used to identify risk factors for experiencing a postoperative complication. Independent samples t tests were used to compare means for neoadjuvant chemotherapy timing and time to commencement of radiation therapy between patients with and without complications. RESULTS: A total of 128 patients were identified. Patients that experienced a complication had a statistically significant difference in time to commencement of radiation therapy (p = 0.021) and an elevated body mass index (p = 0.018) compared with patients who experienced no complication; there was no difference in timing interval of neoadjuvant chemotherapy (p = 0.692). Logistic regression showed an associate between body mass index and postoperative complication (OR, 1.09; 95 percent CI, 1.018 to 1.167; p = 0.013). CONCLUSIONS: Postoperative complications delay the commencement of radiation therapy in patients who received neoadjuvant chemotherapy and undergo mastectomy with immediate breast reconstruction. The period from the last dose of neoadjuvant chemotherapy was equivalent between those that experienced postoperative complications and those that did not. Patients with a higher body mass index are more likely to experience postoperative complications, and this should be considered when offering tissue expanders to obese patients who have received neoadjuvant chemotherapy and require adjuvant radiation treatment. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Teotia SS, Venutolo C, Haddock NT, et al. Outcomes in Patients Receiving Neoadjuvant Chemotherapy Undergoing Immediate Breast Reconstruction: Effect of Timing, Postoperative Complications, and Delay to Radiation Therapy. Plast Reconstr Surg. 2019. PMID: 31688746. doi:10.1097/PRS.0000000000006112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。